口咽癌放疗前后白细胞计数对预后的影响
该回顾性分析纳入137例(基线白细胞/中性粒细胞)和114例(放疗中淋巴细胞)口咽癌患者,比较IMRT与IMPT对淋巴细胞减少的影响,并评估基线中性粒细胞增多、白细胞增多及淋巴细胞最低值与生存的关联。结果显示放疗方式与淋巴细胞减少无关,基线中性粒细胞增多、白细胞增多及放疗中4级淋巴细胞减少与较差生存相关。
要点
- IMRT与IMPT在3级和4级淋巴细胞减少发生率上无显著差异。
- 基线中性粒细胞增多和白细胞增多与较差总生存相关。
- 放疗中4级淋巴细胞减少与较差总生存相关。
核心结论
- 放疗方式(IMRT vs IMPT)不影响放疗期间血细胞计数。
- 基线中性粒细胞增多、基线白细胞增多及放疗中4级淋巴细胞减少与较差预后相关,但需更大样本验证因果。
研究设计与样本
- 回顾性分析来自既往病例对照研究,初始150例口咽癌成人患者,IMRT 100例(2010-2012年),IMPT 50例(2011-2014年)。
- 保留137例有基线白细胞和中性粒细胞记录者进行分析,114例有放疗中淋巴细胞记录者进行分析。
- 采用Cox回归进行多因素生存分析。
主要发现
- 放疗类型与淋巴细胞减少无关(3级P > .99;4级P = .55)。
- 单因素分析中,总生存差与基线中性粒细胞增多(HR 5.58,95%CI 1.99-15.7,P = .001)、基线白细胞增多(HR 4.85,95%CI 1.73-13.6,P = .003)、放疗中4级淋巴细胞减少(HR 3.28,95%CI 1.14-9.44,P = .03)及吸烟>10包年(HR 2.88,95%CI 1.01-8.18,P = .05)相关。
- 多因素分析中仅T分期可能显著(HR 2.64,95%CI 0.99-7.00,P = .05)。
- 无进展生存差在单因素分析中与基线白细胞增多和T分期相关,多因素分析中与基线中性粒细胞增多和高龄相关。
临床怎么用
- 口咽癌放疗前可关注基线中性粒细胞和白细胞水平,其增多提示预后较差。
- 放疗中发生4级淋巴细胞减少提示预后不良,需密切随访。
- IMRT与IMPT对血细胞计数影响无显著差异,选择放疗方式时无需基于此考虑。
局限性
- 回顾性研究设计,样本量有限,统计效能不足。
- 因果关系的建立需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Peripheral blood count components are accessible and evidently predictive in other cancers but have not been explored in oropharyngeal carcinoma. We examine if there is an association between the use of intensity-modulated radiotherapy (IMRT) or intensity-modulated proton therapy (IMPT) and lymphopenia, as well as if there is an association between baseline neutrophilia, baseline leukocytosis and lymphocyte nadir in oropharyngeal cancer. MATERIALS AND METHODS: Analysis started with 150 patients from a previous case to case study design, which retrospectively identified adults with oropharyngeal carcinoma, 100 treated with IMRT in 2010-2012 and 50 treated with IMPT in 2011-2014. Pretreatment leukocyte, neutrophil, lymphocyte, and hemoglobin levels were extracted, as were neutrophil and lymphocyte nadir levels during radiotherapy. We retained 137 patients with recorded pre-treatment leukocyte and neutrophil levels for associated analysis and 114 patients with recorded lymphocyte levels during radiation and associated analysis. Multivariate survival analyses were done with Cox regression. RESULTS: The radiotherapy type (IMRT vs. IMPT) was not associated with lymphopenia (grade 3 P > .99; grade 4 P = .55). In univariate analyses, poor overall survival was associated with pretreatment neutrophilia (hazard ratio [HR] 5.58, 95% confidence interval [CI] 1.99-15.7, P = .001), pretreatment leukocytosis (HR 4.85, 95% CI 1.73-13.6, P = .003), grade 4 lymphopenia during radiotherapy (HR 3.28, 95% CI 1.14-9.44, P = .03), and possibly smoking status >10 pack-years (HR 2.88, 95% CI 1.01-8.18, P = .05), but only T status was possibly significant in multivariate analysis (HR 2.64, 95% CI 0.99-7.00, P = .05). Poor progression-free survival was associated with pretreatment leukocytosis and T status in univariate analysis, and pretreatment neutrophilia and advanced age on multivariate analysis. CONCLUSIONS: Treatment modality did not affect blood counts during radiotherapy. Pretreatment neutrophilia, pretreatment leukocytosis, and grade 4 lymphopenia during radiotherapy were associated with worse outcomes after, but establishing causality will require additional work with increased statistical power.
引用
- Jensen GL, Blanchard P, Gunn GB, et al. Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clin Transl Radiat Oncol. 2017. PMID: 29594226. doi:10.1016/j.ctro.2017.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。